CancerDrs

Lymphoma clinical trials in Nebraska

21 actively recruiting lymphoma trials at 6 sites across Nebraska.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Nebraska:
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Cancer Partners of Nebraska — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Nebraska:
  • Nebraska Medicine-Bellevue — Bellevue, Nebraska
  • Nebraska Medicine-Village Pointe — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Nebraska:
  • Nebraska Medicine-Bellevue — Bellevue, Nebraska
  • Nebraska Medicine-Village Pointe — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Nebraska:
  • Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…

Sponsor: Genmab
NCT ID: NCT06191744
Sites in Nebraska:
  • Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506 — Grand Island, Nebraska
  • NHO - Nebraska Hematology-Oncology /ID# 269692 — Lincoln, Nebraska
  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 262505 — Omaha, Nebraska
  • University of Nebraska Medical Center /ID# 261996 — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in Nebraska:
  • University of Nebraska Medical Center (UNMC) — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Nebraska:
  • Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Nebraska:
  • Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Nebraska:
  • Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Nebraska:
  • NHO Revive Research Institute, LLC ( Site 0121) — Lincoln, Nebraska
  • University Of Nebraska Medical Center ( Site 0110) — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a si…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06090539
Sites in Nebraska:
  • Local Institution - 0124 — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.

Sponsor: March Biosciences Inc
NCT ID: NCT06534060
Sites in Nebraska:
  • University of Nebraska — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Sponsor: CellCentric Ltd.
NCT ID: NCT04068597
Sites in Nebraska:
  • Nebraska Cancer Specialists — Omaha, Nebraska
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Halt Aging in Survivors of Blood Cancers

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do…

Sponsor: University of Nebraska
NCT ID: NCT07292272
Sites in Nebraska:
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…

Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Nebraska:
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists — Omaha, Nebraska
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nebraska:
  • CHI Health Saint Francis — Grand Island, Nebraska
  • Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
  • CHI Health Good Samaritan — Kearney, Nebraska
  • Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
  • Alegent Health Immanuel Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Nebraska:
  • CHI Health Good Samaritan — Kearney, Nebraska
View on ClinicalTrials.gov →
Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Nebraska:
  • University of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Nebraska:
  • Massive Bio SYNERGY-AI site — Omaha, Nebraska
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator st…

Sponsor: Eli Lilly and Company
NCT ID: NCT06876662
Sites in Nebraska:
  • University Of Nebraska Medical Center — Omaha, Nebraska
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25